ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.
Analysts expect the San Diego, California-based company to report quarterly loss of 54 cents per share, versus a loss of 35 cents per share in the year-ago period. The consensus estimate for ARS Pharmaceuticals’ quarterly revenue is $22.12 million (it reported $7.97 million last year), according to Benzinga Pro.
On May 13, ARS Pharmaceuticals named Donn Casale as president.
Shares of ARS Pharmaceuticals fell 0.9% to close at $7.94 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying SPRY stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
